Lupus & antiphospholipid syndrome
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY systemic lupus erythematosus (SLE) phase 2 trial
Authors' conclusion
Whole blood transcriptome profiling via RNA-seq revealed both expected and novel gene expression changes with deucravacitinib across multiple pathogenic pathways.
Study context
- Population
- Patients with SLE in the phase 2 PAISLEY SLE trial, and healthy volunteersplus 56 healthy volunteers
- Participants
- 363 patients
- Comparison
- Deucravacitinib vs placebo; SLE patients vs healthy volunteers
- Healthy volunteersn = 56reference
Methodological detailspost hoc analysis, phase 2, RNA sequencing (RNA-seq), linear mixed-effects models (DREAM), single-sample gene set enrichment analysis (ssGSEA), xCell deconvolution
- Post hoc analysis
- Phase 2
- RNA-seq
- Linear mixed-effects models (DREAM)
- ssGSEA
- xCell deconvolution
Primary result
As reported in the abstract
Whole blood transcriptome changes · baseline to week 32
Differentially expressed genes (DEGs) at baseline, SLE vs healthy volunteers (log2 fold change >1; adjusted P < .05)
527
Genes modulated by deucravacitinib, including interferon-regulated genes
up to 2529
Original publication
Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial. Ann Rheum Dis. Published 12 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →